Comprehensive Multi-Omics Approach To Support Biomarker Programs

In the race to develop targeted therapies, relying on genomics alone can leave critical gaps in your understanding of drug mechanism-of-action. To truly bridge the gap between genomic potential and biological reality, clinical programs must look at the convergence of data.

Our latest infographic outlines a comprehensive approach to multi-omics, highlighting how the integration of different modalities can strengthen your biomarker program:

• Genomics: To profile patient stratification, pharmacogenomics, and ctDNA monitoring.
• Transcriptomics: To profile gene expression and immune response.
• Proteomics: To map pathways and monitor pharmacodynamics.
• Cytomics: To monitor immune cell dynamics, detect circulating tumor cells, track CAR-T expansion, and characterize cellular responses.
• Spatialomics & Pathomics: To see real-time tumor-immune interactions and identify resistance niches.

Understanding how these layers interact is the key to identifying the right patients and proving efficacy earlier in the development cycle.